medigraphic.com

2002, Número 4

<< Anterior Siguiente >>

Vet Mex 2002; 33 (4)


El desafío de las enfermedades priónicas, una emergencia en humanos y bovinos

López-Herrera A, Anne-Lise H, Urcuqui-Inchima S

Idioma: Español/Inglés
Referencias bibliográficas: 83
Paginas: 421-442
Archivo PDF: 142.14 Kb.


RESUMEN

La encefalopatía espongiforme bovina (EEB), más comúnmente conocida como “enfermedad de las vacas locas”, es un malestar transmisible que en forma inesperada y desastrosa ha provocado una crisis severa en la industria cárnica en Europa. La inquietud que propicia la EEB es consecuencia de que la enfermedad es transmisible al hombre y al poco conocimiento que se tiene sobre el mecanismo de transmisión y la patogénesis. Con la presente revisión se pretende presentar una visión general sobre las características de la enfermedad en el bovino y en el humano, así como los avances científicos en este campo, incluyendo aspectos moleculares, celulares y clínicos.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gajdusek DC. Infectious amyloids; subacute spongiform encephalopathies as transmissible cerebral amyloides. En: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. New York: Lippincott Raven Publishers.1996:2851-2900.

  2. 2. Prusiner SB. Prions. En: Fields BN, Knipe DM, Howley PM, editors. Fields Virology. New York: Lippincott Raven Publishers.1996:2901-2950.

  3. 3. Cohen FE, Prusiner SB. Pathologic conformations of prion proteins. Ann Rev Biochem 1998;67:793-819.

  4. 4. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998;95:13363-13383.

  5. 5. Aguzzi A, Heppner FL. Pathogenesis of prion diseases: a progress report. Cell Death Differ 2000;7:889-902.

  6. 6. Jackson GS, Clarke, AR. Mammalian prion proteins. Curr Opin Struct Biol 2000;10:69-74.

  7. 7. Jackson GS, Collinge, J. Prion disease - the propagation of infectious protein topologies. Microbes Infect 2000;2:1445-1449.

  8. 8. Aguzzi A, Montrasio F, Kaeser PS. Prions: health scare and biological challenge. Nature Rev Mol Cell Biol 2001;2:118-126.

  9. 9. Caughey B, editor. Prion proteins. Adv Prot Chem. 2001;57.

  10. 10. Caughey B, Chesebro B. Transmissible spongiform encephalopathies and prion protein interconversions. Adv Virus Res 2001;56:277-311.

  11. 11. Aguzzi A, Brandner S, Fischer MB, Furukawa H, Glatzel M, Hawkins C, et al. Spongiform encephalopathies: insights from transgenic models. Adv Virus Res 2001;56:313-352.

  12. 12. Schwartz M. Comment les vaches sont devenues folles. Paris, France: Odile Jacob, Publications. 2001.

  13. 13. Polo JM. Historia y clasificación de las enfermedades priónicas humanas. Rev Neurol 2000;31:137-141.

  14. 14. Eigen M. Priones y encefalopatía espongiforme bovina. Invest Cienc 2001;298:74-83.

  15. 15. Brown P, Will R, Bradley R, Asher D, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis 2001;7:6-16.

  16. 16. Cuillé J, Chelle PL. Pathologie animale - la maladie dite tremblante du mouton est-elle inoculable? C r Acad Sci (D) Paris 1936;203:1552-1554.

  17. 17. Chandler RL. Encephalopathy in mice produced by inoculation with scrapie brain material. Lancet 1961;1:1378-1379.

  18. 18. Marsh RF, Kimberlin RH. Comparison of scrapie and transmissible mink encephalopathy in hamsters. II. Clinical signs, pathology and pathogenesis. J Infect Dis 1975;131:104-110.

  19. 19. Brown P, Gajdusek DC. Survival of scrapie virus after 3 years’ interment. Lancet 1991; 337:269-270.

  20. 20. Hadlow WJ. Scrapie and kuru. Lancet 1959;2:289-290.

  21. 21. Klatzo I, Gajdusek DC, Zigas V. Pathology of kuru. Lab Invest 1959;8:799-847.

  22. 22. Gajdusek DC, Gibbs CJ, Alpers M. Experimental transmission of a kuru-like syndrome in chimpanzees. Nature 1966;209:794-796.

  23. 23. Gajdusek DC, Gibbs CJ, Alpers M. Transmission and passage of experimental “kuru” to chimpanzees. Science 1967;155:212-214.

  24. 24. Collee JG, Bradley R. BSE: a decade on-Part 1. Lancet 1997;349:636-641.

  25. 25. Fishbein L. Transmissible spongiform encephalopathies, hypotheses and food safety: an overview. Sci Total Environ 1998;217:9871-9882.

  26. 26. Ossa JE, Machado G, Giraldo MA, McEwen JG. Prion plaques: molecular tumors. A hypothesis on the etiopathogenesis of prion diseases. Med Hypotheses 1995;44:124-126.

  27. 27. Wadsworth JDF, Joiner S, Hill AF, Campbell TA, Desbruslais M, Luthert PJ, Collinge, J. Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 2001;358:171-180.

  28. 28. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc Natl Acad Sci USA 1997;94:10069-10074.

  29. 29. Brown P, Rau EH, Johnson BK, Bacote AE, Gibbs CJ, Gajdusek DC. New studies on the heat resistance of hamster-adapted scrapie agent: threshold survival after ashing at 600°C suggests an inorganic template of replication. Proc Natl Acad Sci USA 2000;97:3418-3421.

  30. 30. Jackson GS, Murray I, Hosszu LLP, Gibbs N, Waltho JP, Clarke AR, Collinge J. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci USA 2001;98:8531-8535.

  31. 31. Shaked Y, Rosenmann H, Hijazi N, Halimi M, Gabizon R. Copper binding to the PrP isoforms: a putative marker of their conformation and function. J Virol 2001;75:7872-7874.

  32. 32. Brown DR. Copper and prion disease. Brain Res Bull 2001;55:165-173.

  33. 33. Piccardo P, Safar J, Ceroni M, Gajdusek DC, Gibbs CJ . Immunohistochemical localization of prion protein in spongiform encephalopathies and normal brain tissue. Neurology 1990;40:518-522.

  34. 34. Hansen LA, Masliah E, Terry RD, Mirra SS. A neuropathological subset of Alzheimer’s disease with concomitant Lewy body disease and spongiform change. Acta Neuropathol 1989;78:194-201.

  35. 35. Zahn R, Liu A, Lührs T, Riek R, Von-Scroetter C, Lopez-Garcia F, et al. NMR solution structure of human prion protein. Proc Natl Acad Sci USA 2000;97:145-150.

  36. 36. Lopez-Garcia F, Zahn R, Riek R, Wüthrich K. NMR structure of the bovine prion protein. Proc Natl Acad Sci USA 2000;97:8334-8339.

  37. 37. Pan KM, Baldwin MA, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of a-helices into b-sheet feature in the formation of the scrapie prion proteins. Proc Natl Acad Sci USA 1993;90:10962-10966.

  38. 38. Bueler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993;73:1339-1347.

  39. 39. Korth C, Stierli B, Streit P, Moser M, Schaller O, Fischer R, et al. Prion (PrPSC)-specific epitope defined by a monoclonal antibody. Nature 1997;390:74-77.

  40. 40. Peretz D, Williamson RA, Kaneko K, Vergara J, Leclerc E, Schmitt-Ulms G, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001;412:739-743.

  41. 41. Economic impact of BSE on the UK economy, report to UK agricultural departments & HM treasury. Edimburg: DTZ Pieda Consulting, 1998. En: http://www.bse.org.uk/files/mb/m11/tab02.pdf (revisado en noviembre de 2001).

  42. 42. Ferguson NM, Donnelly CA, Woolhouse ME, Anderson RM. The epidemiology of BSE in cattle herds in Great Britain. II. Model construction and analysis of transmission dynamics. Philos Trans R Soc Lond B Biol Sci 1997;352:803-838.

  43. 43. Marsh RF. Bovine spongiform encephalopathy: a new disease of cattle? Arch Virol Suppl 1993;7:255-259.

  44. 44. Cohen CH, Valleron AJ. When did bovine spongiform encephalopathy (BSE) start? Implications on the prediction of a new variant of Creutzfeldt-Jakob disease (nvCJD) epidemic. Int J Epidemiol 1999;28:526-531.

  45. 45. Ferguson NM, Donnelly CA, Woolhouse ME, Anderson RM. Estimation of the basic reproduction number of BSE: the intensity of transmission in British cattle. Proc R Soc Lond B Biol Sci 1999;266:23-32.

  46. 46. Goldwater PN. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: implications for Australia. Med J Aust 2001;175:154-158.

  47. 47. Wilesmith JW, Ryan JB, Atkinson MJ. Bovine spongiform encephalopathy: epidemiological studies on the origin. Vet Rec 1991;128:199-203.

  48. 48. MacKnight C. Clinical implications of bovine spongiform encephalopathy. Clin Infect Dis 2001;32:1726-1731.

  49. 49. Maignien T, Lasmézas CI, Beringue V, Dormont D, Deslys JP. Pathogenesis of the oral route of infection of mice with scrapie and bovine spongiform encephalopathy agents. J Gen Virol 1999;80:3035-3042.

  50. 50. Donnelly CA, Ferguson NM, Ghani AC, Wilesmith JW, Anderson RM. Analysis of dam-calf pairs of BSE cases: confirmation of a maternal risk enhancement. Proc R Soc Lond B Biol Sci 1997;264:1647-1656.

  51. 51. Wilesmith JW, Wells GA, Ryan JB, Gavier-Widen D, Simmons MM. A cohort study to examine maternally-associated risk factors for bovine spongiform encephalopathy. Vet Rec 1997;141:239-243.

  52. 52. Dixon B. Hindsight blinkers Britain’s mad cow disease response. Curr Biol 2000;10:R847,R848.

  53. 53. Walton TE. The impact of diseases on the importation of animals and animal products. Ann NY Acad Sci 2000;916:36-40.

  54. 54. Patterson WJ, Painter MJ. Bovine spongiform encephalopathy and new variant Creutzfeldt-Jakob disease: an overview. Commun Dis Public Health 1999;2:5-13.

  55. 55. Lasmézas CI, Fournier JG, Nouvel V, Boe H, Marcé D, Lamoury F, et al. Adaptation of the bovine spongiform encephalopathy agent to primates and comparison with Creutzfeldt-Jakob disease: implications for human health. Proc Natl Acad Sci USA 2001;98:4142-4147.

  56. 56. Narang H. Origin and implications of bovine spongiform encephalopathy. Proc Soc Exp Biol Med 1996;211:306-22.

  57. 57. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature 1991;352:340-342.

  58. 58. Variant Creutzfeldt-Jakob disease (vCJD). En: www.who.int/inf-fs/en/fact180.html (Fact Sheet No. 180; revisado en junio 2001).

  59. 59. Hill AF, Desbruslais M, Joines S, Sidle KC, Gowland I, Collinge J, et al. The same prion strain causes vCJD and BSE. Nature 1997;389:448-450.

  60. 60. Will RG, Zeidler M, Stewart GE, Macleod MA, Ironside JW, Cousens S, et al. Diagnosis of new variant Creutzfeldt-Jacob diseases. Ann Neurol 2000;47:575-582.

  61. 61. Lloyd SE, Onwuazor ON, Beck JA, Mallison G, Farall M, Targonski P, et al. Identification of multiple quantitative trait loci linked to prion disease incubation period in mice. Proc Natl Acad Sci USA 2001;98:6279-6283.

  62. 62. Collinge J, Beck J, Campbell T, Estibeiro K, Will RG. Prion protein gene analysis in new variant cases of Creutzfeldt-Jakob disease. Lancet 1996;348:56-57.

  63. 63. Moore RM, Xiang F, Monagham J, Han D, Zhang Z, Edström L, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet 2001;69:1385-1388.

  64. 64. Hill AF, Zeidler M, Ironside J, Collinge J. Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 1997;349:99-100.

  65. 65. Foulkes N. A new dimension to the vCJD epidemic: multiple QTL. Trends Genetics 2001;17:439.

  66. 66. Número de casos de encefalopatía espongiforme bovina señalados en el Reino Unido. En: www.oie.int/esp/info/es_esbru.htm (revisado en noviembre de 2001).

  67. 67. Número de casos de encefalopatía espongiforme bovina señalados en el mundo (con excepción del Reino Unido). En: www.oie.int/esp/info/es_esbmonde.htm (revisado en noviembre de 2001).

  68. 68. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, Chen SG, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jacob disease. Ann Neurol 1996;39:767-778.

  69. 69. Hecker R, Taraboulos A, Scott M, Pan KM, Yang SL, Torchi M, et al. Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters. Genes Dev 1992;6:1213-1228.

  70. 70. Taraboulos A, Jendroska K, Serban D, Yang SL, DeArmond SJ, Prusiner SB. Regional mapping of prion proteins in brain. Proc Natl Acad Sci USA 1992;89:7620-7624.

  71. 71. Schulz-Schaeffer WJ, Tschöke S, Kranefuss N, Dröse W, Hause-Reitner D, Giese A, et al. The paraffin-embedded tissue blot detects PrP(Sc) early in the incubation time in prion diseases. Am J Pathol 2000;156:51-56.

  72. 72. Ricketts MN. Infection control guidelines for TSEs in hospitals and home care settings. Abstract book. International Symposium on “Prion Diseases and Related Processes”; Les Pensières, France. Fondation Mérieux, Lyon, France. 2000:69-73.

  73. 73. Chen ZL, Strickland S. Neural death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997;91:917-925.

  74. 74. Tsirka SE, Rogove AD, Strickland S. Neural cell death and tPA. Nature 1996;384:123-124.

  75. 75. Fischer MB, Roecki C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature 2000;408:479-483.

  76. 76. Caspi S, Halimi M, Yanai A, Sasson SB, Taraboulos A, Gabizon R. The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 1998;273:3484-3489.

  77. 77. Korth C, May BCH, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci USA 2001;98:9836-9841.

  78. 78. Wickner RB. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 1994;264:566-569.

  79. 79. Serio TR, Lindquist SL. [PSI+]: an epigenetic modulator of translation termination efficiency. Ann Rev Cell Dev Biol 1999;15:661-703.

  80. 80. Koo EH, Landsbury PT, Kelly IW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 1999;96:9989-9990.

  81. 81. Michelitsch MD, Weissman JS. A census of glutamine/asparagine-rich regions: implications for their conserved function and the prediction of novel prions. Proc Natl Acad Sci USA 2000;97:11910-11915.

  82. 82. Dove A. US throws money at TSE research. Nature Med 2001;7:1075.

  83. 83. Collee JG, Bradley R. BSE: a decade on - Part 2. Lancet 1997;349:715-721.




2020     |     www.medigraphic.com